Not all immune checkpoint inhibitor-induced myositis are alike

Spanish and American researchers studied the clinical and serological data of patients with autoimmune myositis in relation to immune checkpoint inhibitor (ICI) treatment.

• Transcriptomic analysis were performed using RNAmacromolécule constituée d’une seule chaîne de nucléotides (simple brin) résultant de la transcription (copie) de l’ADN. extracted from muscle biopsies,
• 35 biopsies from patients with ICI myositis were selected from 200 others,
• 3 transcriptomic profiles emerged (ICI-DM, ICI-MYO1 and ICI-MYO2), some of which had distinct clinical characteristics, particularly with regard to the presence of disturbances in the interferon pathway and/or the risk of myocarditis.

This study will help to better adjust the management and monitoring of this type of inflammatory myopathy of autoimmune origin.

Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis. Pinal-Fernandez I, Quintana A, Milisenda JC, et al. Ann Rheum Dis. 2023 Feb 17:ard-2022-223792.